QUOTE AND NEWS
newratings.com  Oct 24  Comment 
WASHINGTON (dpa-AFX) - Molecular diagnostics company Cepheid (CPHD) said that antitrust clearances have been received or the requisite waiting periods have expired, as applicable, in the United States, Germany, Austria and South Africa, for the...
Benzinga  Sep 26  Comment 
In a note released Monday, Barclays said about four companies sought to bid for Cepheid (NASDAQ: CPHD). This follows a review of the proxy statement released by the company last Friday regarding its announced acquisition by Danaher Corporation...
Benzinga  Sep 12  Comment 
  Bank of America downgraded Edgewell Personal Care Co (NYSE: EPC) from Buy to Neutral. Edgewell Personal Care shares fell 1.22 percent to $76.07 in pre-market trading. Baird downgraded Cepheid (NASDAQ: CPHD) from Outperform to...
Benzinga  Sep 7  Comment 
BTIG sees competing bids for Cepheid (NASDAQ: CPHD) unlikely following its deal to be acquired by Danaher Corporation (NYSE: DHR) for $53 a share in cash. "Though the purchase price is essentially in line with CPHD's 52-week high ($53.19), we...
newratings.com  Sep 7  Comment 
WASHINGTON (dpa-AFX) - In 26 trading days, after featuring on Short-Term Investor, Cepheid (CPHD) returned about 50% to investors. The stock was featured on our 'Short-Term Investor' on July 29 at an opening price of $35.13. Yesterday,...
Motley Fool  Sep 6  Comment 
Shares jump on the news that the company is being bought out by Danaher.
Benzinga  Sep 6  Comment 
  Following the market opening Tuesday, the Dow traded up 0.22 percent to 18,531.96 while the NASDAQ gained 0.28 percent to 5,264.58. The S&P also rose, gaining 0.14 percent to 2,182.94. Leading and Lagging Sectors Tuesday morning,...
Benzinga  Sep 6  Comment 
Danaher Corporation (NYSE: DHR) disclosed Tuesday that it reached a definitive merger deal with Cepheid (NASDAQ: CPHD) to buy the latter for $53.00 a share in cash. The total enterprise value of the transaction is approximately $4 billion, which...
Reuters  Sep 6  Comment 
* Cepheid will be required to pay Danaher termination fee of $131 million in certain circumstances, including if Cepheid terminates merger deal Source text: (http://bit.ly/2cwGuam)




RELATED WIKI ARTICLES

Related Articles

 
TOP CONTRIBUTORS

Cepheid is a molecular diagnostics company that develops, manufactures, and markets fully-integrated systems for genetic analysis in the clinical molecular diagnostic, industrial, and biothreat markets. These systems enable rapid, sophisticated molecular testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. Molecular testing involves a number of complicated and time-intensive steps, including sample preparation, DNA amplification, and detection. Cepheid's easy-to-use systems integrate these steps and analyze complex biological samples. The company is focusing efforts on those applications where rapid molecular testing is particularly important, such as identifying infectious disease and cancer in the clinical molecular diagnostic market food, agricultural and environmental testing in the industrial market and identifying bio-terrorism agents in the biothreat market. In 2006, clinical molecular diagnostic, biothreat, and industrial markets contributed 24%, 58%, and 18% respectively to total revenue. The company's initial public offering of stock was on June 21, 2000.

The company derives revenues primarily from the sales of its two instrument platforms and associated reagents and disposables in the clinical molecular diagnostic, industrial, and biothreat markets, and to a lesser extent from contract and government sponsored research. The two principal instrument platforms are the SmartCycler and GeneXpert systems. The SmartCycler system, integrates DNA amplification and detection to allow rapid analysis of a sample. The GeneXpert system integrates automated sample preparation with the SmartCycler DNA amplification and detection technology. The GeneXpert system, a closed, self-contained, fully-integrated and automated system, represents a paradigm shift in the automation of molecular analysis, producing accurate results in a timely manner with minimal risk of contamination. The GeneXpert system can provide rapid results with superior test specificity and sensitivity over comparable systems on the market today that are integrated but have open architectures. In 2006, instrument sales, reagent/disposable sales, contract revenue, and grant/government sponsored research revenue contributed 26%, 68%, 5%, and 1% respectively to total revenue.




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki